Who
Farrell Simon
Director
Company insider
Files Form 4 as: Director, Serina Therapeutics; Chief Commercial Officer, Trevi Therapeutics.
In numbers
- Trades disclosed
- 21
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $549K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 16 Feb 2023
- Last trade
- 22 Jul 2026
- Last filed
- 23 Jul 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jul 2026filed 23 Jul 2026 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,500 at $0.00 | filing |
| 22 Jul 2026filed 23 Jul 2026 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,500 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —160,000 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —160,000 at $0.00 | filing |
| 31 May 2025filed 3 Jun 2025 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —72,000 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,400 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,500 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —63,813 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —31,250 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Code M | $56K17,500 at $3.21 | filing |
| 10 Mar 2025filed 12 Mar 2025 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Code M | $250K63,813 at $3.91 | filing |
| 10 Mar 2025filed 12 Mar 2025 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Code M | $16K31,250 at $0.51 | filing |
| 10 Mar 2025filed 12 Mar 2025 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Sold | $518K76,963 at $6.73 | filing |
| 10 Mar 2025filed 12 Mar 2025 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Sold | $31K4,350 at $7.15 | filing |
| 18 Feb 2025filed 20 Feb 2025 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,500 at $0.00 | filing |
| 15 Feb 2024filed 16 Feb 2024 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 20 Jun 2023filed 21 Jun 2023 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,250 at $0.00 | filing |
| 20 Jun 2023filed 21 Jun 2023 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Code M | $3,1886,250 at $0.51 | filing |
| 7 Mar 2023filed 8 Mar 2023 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,750 at $0.00 | filing |
| 7 Mar 2023filed 8 Mar 2023 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Code M | $9,56318,750 at $0.51 | filing |
News
Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual MeetingTRVI · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Farrell Simon; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.